Epimmune, Inc.

Patent granted for Epitope-based vaccines targeting hepatitis B virus

Published in Drug Law Weekly, March 16th, 2004

Epimmune, Inc., (EPMN) announced the issuance of U.S. Patent No. 6,689,363, directed to compositions and methods of using antigen fragments, or epitopes, to induce cellular, or T cell, immune responses for the prevention or treatment of hepatitis B virus (HBV) infection.

The issued claims are directed to vaccine compositions made up of epitopes from multiple HBV proteins, identified using Epimmune's proprietary epitope identification technology, designed to provide broader population coverage than prior vaccines.

Emile Loria, president and CEO of Epimmune said, "This is an important patent for the company coming shortly after our partner, Genencor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-03-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry